B4Deals
CordenPharma plans about €900 million to grow peptide capacity in Europe and the US
The contract maker owned by Astorg said it would invest about €900 million over three years, much of it in a large new peptide plant.
Dateline
Boulder, Colorado
Automated microwave peptide synthesizer (laboratory scale) Photo: Chrumps, CC BY-SA 4.0, via Wikimedia Commons (cropped)
In one lineA mid-sized contract maker bets heavily that drug companies will keep outsourcing peptide chemistry.
What was announced
CordenPharma, a contract drug maker, said it would invest about €900 million over roughly three years to expand its peptide platform and related work in the US and Europe.
What it covers
The plan included a new large-scale peptide ingredient facility in the US, expansion at its Colorado site, and investment in lipids and sterile filling in Europe.
Why contract makers are growing
Many peptide drugs in development come from companies without their own plants. They need a contract maker that can scale from clinical batches to commercial tonnes. Demand for GLP-1 and related peptides took up much of the existing space.
Competition
CordenPharma competes with Bachem, PolyPeptide and Asian CDMOs. All of them announced expansions between 2023 and 2025.
The caveat
Contract makers often announce totals before every site is fixed. Treat the €900 million as a plan.
What it changes for supply
Independent peptide capacity is thin. Each new contract plant gives smaller drug developers somewhere to go besides the two GLP-1 giants.
Still open
Final site choices, customer names and how much of the plan is tied to signed contracts.
SourceCordenPharma announcement, February 2024
Peptide Global covers how medicines are made and traded. Nothing here is medical advice.
